[
  {
    "ts": "2026-01-13T02:06:44+00:00",
    "headline": "Adaptive Biotechnologies Touts clonoSEQ MRD Growth, Targets Companywide Profitability in 2026",
    "summary": "Adaptive Biotechnologies (NASDAQ:ADPT) used a presentation at the J.P. Morgan healthcare conference to outline growth drivers for its clonoSEQ minimal residual disease (MRD) franchise and to describe a capital-disciplined strategy for its immune medicine (IM) unit, while also reiterating an expectat",
    "url": "https://www.marketbeat.com/instant-alerts/adaptive-biotechnologies-touts-clonoseq-mrd-growth-targets-companywide-profitability-in-2026-2026-01-12/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "6a47b310-4337-38a6-a42f-7234fb2398ba",
      "content": {
        "id": "6a47b310-4337-38a6-a42f-7234fb2398ba",
        "contentType": "STORY",
        "title": "Adaptive Biotechnologies Touts clonoSEQ MRD Growth, Targets Companywide Profitability in 2026",
        "description": "",
        "summary": "Adaptive Biotechnologies (NASDAQ:ADPT) used a presentation at the J.P. Morgan healthcare conference to outline growth drivers for its clonoSEQ minimal residual disease (MRD) franchise and to describe a capital-disciplined strategy for its immune medicine (IM) unit, while also reiterating an expectat",
        "pubDate": "2026-01-13T02:06:44Z",
        "displayTime": "2026-01-13T02:06:44Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/baa5b0d6d1008ef08fbab74e80859778",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Adaptive Biotechnologies logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vl3KxAbO6Qy1kY4gwcWiQw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/baa5b0d6d1008ef08fbab74e80859778.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/k0aX39WhsUnMUyzB.8sxJg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/baa5b0d6d1008ef08fbab74e80859778.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/adaptive-biotechnologies-touts-clonoseq-mrd-growth-targets-companywide-profitability-in-2026-2026-01-12/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/adaptive-biotechnologies-touts-clonoseq-mrd-020644870.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ADPT"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]